ViroPharma Inc. (VPHM) reported a fourth-quarter GAAP net loss of $3.9 million or $0.06 per share compared to a GAAP net income of $53.1 million or $0.65 per share in the fourth quarter of 2011.
However, on an adjusted basis the company posted a profit of $7.1 million, or $0.10 per share.
Meanwhile, net sales fell to $106.49 million for the fourth quarter, from $145.57 million in the same three months of 2011.
Analysts polled by Thomson Reuters expected the company to report earnings of $0.03 per share on revenues of $103.06 million for the quarter. Analysts' estimates typically exclude special items.
For the year 2013, ViroPharma expects Worldwide net product sales to be in the range $450 million to $475 million, reflective of updated expectations for Vancocin. Net U.S. Cinryze sales are expected to be $390 million to $400 million.
For comments and feedback: editorial@rttnews.com